FREE SHIPPING ON ORDERS $70+FAST U.S. FULFILLMENTBATCH DOCUMENTATION

BPC-157 vs GHK-Cu: How Two Popular Research Peptides Differ

By The Bionova Club Team

Research use only. Bionova products are sold strictly for in-vitro and laboratory research by qualified professionals. They are not drugs, food, or cosmetics, are not approved by the FDA, and are not for use in people or animals. Nothing in this article is medical advice or a claim about effects in people.

Disclosure: Bionova Club sells BPC-157, GHK-Cu and blends that contain both, all linked below.

BPC-157 and GHK-Cu turn up side by side in search results, in lab catalogs and inside the same multi-peptide blends. That makes it easy to assume they are close relatives. They are not. One is a 15-residue synthetic peptide traced to a gastric protein. The other is a three-residue peptide that carries a copper ion. They differ in size, chemistry, history and in the kinds of experiments that have been run with them.

This guide compares the two by structure, origin and the models in which they have been studied. It does not describe outcomes, and nothing here should be read as a prediction of what either compound does outside a laboratory model. If you are new to peptide basics, start with our primer, What Are Peptides?

BPC-157 vs GHK-Cu at a glance

  • Length
    • BPC-157: 15 amino acids (a pentadecapeptide)
    • GHK-Cu: 3 amino acids (a tripeptide) bound to one copper(II) ion
  • Sequence
    • BPC-157: GEPPPGKPADDAGLV
    • GHK-Cu: Gly-His-Lys (glycyl-L-histidyl-L-lysine), complexed with Cu²⁺
  • Molecular formula (PubChem)
  • Approximate molar mass
    • BPC-157: about 1,419.5 g/mol
    • GHK-Cu: about 340 g/mol for GHK alone, and roughly 400 g/mol once copper is included
  • Origin story
    • BPC-157: described as a partial sequence of "body protection compound," a protein reported in gastric juice
    • GHK-Cu: GHK was first reported in 1973 by Pickart and colleagues; its copper complex became the main research form
  • Appearance as supplied
    • BPC-157: lyophilized powder
    • GHK-Cu: blue to blue-violet lyophilized powder, colored by the copper
  • Typical research models
    • BPC-157: rodent tissue models, tendon fibroblast cultures, isolated blood vessel preparations
    • GHK-Cu: fibroblast cultures, gene-expression datasets, formulation research

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide. The name comes from "body protection compound," a larger protein described in gastric juice, and BPC-157 is usually presented as a stable fragment of that protein. Because of that origin, much of the early literature sits in gastrointestinal research. The peptide also appears in the literature under the codes PL 14736 and Bepecin.

Models in which BPC-157 has been studied

Most published BPC-157 work is preclinical, meaning it was done in cell culture or in animals. Two lines of in-vitro and ex-vivo work are often cited because they look at cellular mechanisms rather than whole-animal endpoints:

  • Tendon fibroblasts. Chang and colleagues isolated fibroblasts from rat Achilles tendon and used cDNA microarray analysis, RT-PCR and Western blotting to study gene and protein expression after exposure to BPC-157. Growth hormone receptor was among the genes they reported as up-regulated, along with downstream JAK2 signaling in that culture system (Chang et al., 2014, Molecules).
  • Vascular tissue. Hsieh and colleagues studied BPC-157 in isolated rat aorta and in cultured vascular endothelial cells. They examined vasomotor tone, nitric oxide generation and the Src-Caveolin-1-eNOS signaling pathway (Hsieh et al., 2020, Scientific Reports).

A 2025 systematic review screened the BPC-157 literature from an orthopaedic perspective. Of the 36 studies it included, 35 were preclinical (Vasireddi et al., 2025, HSS Journal).

What is GHK-Cu?

GHK is the tripeptide glycine-histidine-lysine. It binds copper(II) ions with high affinity, and the copper complex is called GHK-Cu. Most research uses the complex rather than the free peptide, and the copper is what gives the material its blue color.

A short history

GHK entered the literature in 1973. Pickart and Thaler first described a tripeptide in human serum that affected the survival and growth of liver cells (Pickart & Thaler, 1973, Nature New Biology), and a follow-up paper the same year reported the synthetic tripeptide's effects on cultured normal liver and hepatoma cells (Pickart et al., 1973, Biochemical and Biophysical Research Communications). Its copper binding was characterized afterward: Pickart and colleagues reported in 1980 that the tripeptide readily forms complexes with copper(II) (Pickart et al., 1980, Nature), and a 1981 potentiometric study measured the stability of those copper(II) complexes (Lau & Sarkar, 1981, Biochemical Journal).

Models in which GHK-Cu has been studied

  • Fibroblast cultures. In 1988, Maquart and colleagues studied the GHK-Cu complex in fibroblast cultures and reported changes in collagen synthesis in that system (Maquart et al., 1988, FEBS Letters). This work underpins much of the later interest in GHK-Cu as a tool in extracellular matrix biology.
  • Gene-expression datasets. A 2018 review by Pickart and Margolina summarizes analyses of public gene-expression data in which GHK was associated with expression changes across many genes (Pickart & Margolina, 2018, International Journal of Molecular Sciences). Associations of this kind are hypothesis-generating; they are not demonstrations of effects in whole organisms.

The 2018 review above is co-authored by Loren Pickart, who first reported GHK in 1973.

Key differences between BPC-157 and GHK-Cu

Size and chemistry

BPC-157 is roughly four times the molar mass of GHK (1,419.5 vs 340.4 g/mol) and is a linear peptide with no bound metal. GHK-Cu is a small metal-peptide complex in which the tripeptide holds a copper(II) ion. That makes GHK-Cu as much a coordination-chemistry topic as a peptide one, and it is why GHK-Cu appears in metal-binding and formulation research while BPC-157 does not.

Research history

The two compounds come from separate research traditions. BPC-157 work grew out of gastrointestinal research on a gastric protein. GHK work grew out of liver-cell culture studies and later moved into matrix biology and copper biochemistry. To our knowledge, head-to-head studies comparing the two peptides are scarce.

Mechanisms studied

  • BPC-157
    • Growth-factor and receptor expression in tendon fibroblasts
    • Nitric oxide and eNOS-related signaling in vascular preparations
  • GHK-Cu
    • Collagen and extracellular matrix synthesis in fibroblast cultures
    • Copper-binding chemistry
    • Gene-expression associations from public datasets

Physical form

Both are typically supplied as lyophilized powders. GHK-Cu is visibly blue because of its copper, which is an easy visual cue on a bench, though identity should always be confirmed by the documentation that ships with the material.

Why they appear together in research blends

Because BPC-157 and GHK-Cu are studied in different but adjacent research areas, some labs want both in the same experimental series. That is the reasoning behind multi-peptide blends:

  • GLOW combines GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg (70 mg total) in one vial.
  • KLOW contains GHK-Cu, BPC-157, TB-500 and KPV.
  • Wolverine pairs BPC-157 with TB-500, without GHK-Cu.

To our knowledge, the GLOW and KLOW combinations have not been studied as blends in the published literature, and the research cited in this article was done on the individual compounds. A blend is a format choice for study design; it is not a separately characterized substance. Researchers who need to isolate the contribution of each component generally work with the single peptides, BPC-157 and GHK-Cu. You can browse all multi-peptide formats in our blends category.

Key takeaways

  • BPC-157 is a 15-residue linear peptide; GHK-Cu is a three-residue peptide bound to copper.
  • They come from separate research traditions: gastric-protein research for BPC-157, liver-cell culture and matrix biology for GHK-Cu.
  • Most published work on both is preclinical, done in cell culture or animal models.
  • Blends such as GLOW and KLOW combine the two; to our knowledge those blends have not been characterized in the published literature.
  • Both are research materials only and are not approved for use in people.

Frequently asked questions

Is GHK-Cu a fragment of BPC-157?

No. The two sequences are unrelated. BPC-157 is GEPPPGKPADDAGLV; GHK is Gly-His-Lys. GHK-Cu is not contained in BPC-157 and is not derived from it.

Why is GHK-Cu blue?

The blue color comes from the copper(II) ion bound to GHK. BPC-157 carries no metal, so it lacks that color.

Have BPC-157 and GHK-Cu been compared directly?

Direct comparisons are scarce. The two have mostly been studied separately, in different model systems, so the literature does not support ranking one against the other.

Which should a lab choose?

That depends on the question being studied. Work on copper-peptide chemistry or matrix synthesis in fibroblast culture generally points to GHK-Cu. Work that builds on the gastric-peptide or tendon-fibroblast literature generally points to BPC-157.

Shop for your research: BPC-157 and GHK-Cu, or the GLOW and KLOW blends that contain both, for laboratory research. Use code CLUB10 at checkout for 10% off.

References

  1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973. https://pubmed.ncbi.nlm.nih.gov/4349963/
  2. Pickart L, Thayer L, Thaler MM. A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. Biochem Biophys Res Commun. 1973. https://pubmed.ncbi.nlm.nih.gov/4356974/
  3. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. https://pubmed.ncbi.nlm.nih.gov/3169264/
  4. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. https://pubmed.ncbi.nlm.nih.gov/29986520/
  5. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. https://pubmed.ncbi.nlm.nih.gov/25415472/
  6. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020. https://pubmed.ncbi.nlm.nih.gov/33051481/
  7. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
  8. Pickart L, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980. https://pubmed.ncbi.nlm.nih.gov/7453802/
  9. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981. https://pubmed.ncbi.nlm.nih.gov/7340824/

For laboratory research use only. Not for human consumption.